ANDREA MEALOR: Open Payments
NPI 1386918316 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,840 in 159 payments from 20 companies in 2025. Trend: 2023 $1,908 · 2024 $2,204 · 2025 $2,840
Food & beverage: $2,763Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $666 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 27 | $362 |
| Janssen Biotech, Inc. | 12 | $280 |
| Ardelyx, Inc. | 16 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $202 |
| Regeneron Healthcare Solutions, Inc. | 6 | $144 |
| Lilly USA, LLC | 9 | $141 |
| GENZYME CORPORATION | 5 | $121 |
| QOL Medical, LLC | 4 | $99 |
| Ipsen Biopharmaceuticals, Inc | 4 | $88 |
Products named: XIFAXAN, TREMFYA, DUPIXENT, IBSRELA, RINVOQ, ENTYVIO, SKYRIZI, OMVOH.
Industry payments across GA — which companies pay providers there.
